NFKB1 and prostate carcinoma: Additionally, ibuprofen (1–3 mM) is able to inhibit nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) activation by preventing the degradation of IκBα, the NF-κB inhibitory protein, in prostate cancer [30].